Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours

Maja de Jonge, SB Kaye, Jaap Verweij, C Brock, S Reade, M Mcurr, L van Doorn, Coleta Verheij, Walter Loos, CJ Brindley, P Mistry, M Cooper, I Judson

Research output: Contribution to journalArticleAcademicpeer-review

23 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)1459-1465
Number of pages7
JournalBritish Journal of Cancer
Publication statusPublished - 2004

Research programs

  • EMC MM-03-86-08

Cite this